Startup · $28.8m raised
Melbourne, VIC
Programs: Brandon BioCatalyst (CUREator+ Dementia & Cognitive Decline)
Every investor coverage indicates participated in a round Kinoxis Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Australian Government | Grant | - |
| Avicella Capital | Unnamed stage · Series B | - |
| Brandon BioCatalyst | Accelerator | - |
| CUREator+ | Grant | - |
| Main Sequence Ventures | Unnamed stage | $5,000,000 |
| MainSequence | Unnamed stage | $5,000,000 |
| Medical Research Future Fund | Grant | - |
| Stoic Venture Capital | Unnamed stage · Series B | - |
| The University of Sydney | Unnamed stage · Series B | - |
| Uniseed | Unnamed stage · Series B | - |
| UniSuper | Unnamed stage · Series B | - |
Companies Kinoxis Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Hugh Alsop | CEO | Uniseed, SmartCompany, kinoxistherapeutics.com |
| Dr Peter Devine | Chairman (former) | kinoxistherapeutics.com |
| Dr Elaine Stead | Director (former) | Uniseed, Startup Daily |
Stories naming Kinoxis Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of deep tech investor Main Sequence covering Elaine Stead's promotion to Partner, portfolio unicorns Gilmour Space and Advanced Navigation, CSIRO's expanded Atmosphere backing, and a fourth fund now being raised.
Also OIF Ventures portfolio·OIF Ventures portfolio·SmartCompany·@AuManufacturing·SmartCompany·SmartCompany·SmartCompany·@AuManufacturing·Forbes Australia
Main Sequence announces Elaine Stead's promotion to Partner while preparing its fourth fund; CSIRO has lifted its commitment to the firm's Atmosphere pre-seed program, and two portfolio companies have reached unicorn status.
Weekly roundup recording a dozen raises and acquisitions, Firmus's scheduled float, a new $50m venture fund, a founder share sale, grant winners, an accelerator intake, and an AI agent's government breach.
Also DealStreetAsia·Dealroom·This Week in Australian Startups·AFR Technology·AFR Technology·Startup Daily·AFR Technology·AFR Technology·ABC News Technology·iTnews
Melbourne biotech Kinoxis completed a $6.75 million round with new backer MainSequence and won a $2.5 million government-funded CUREator+ grant for dementia and pain drug development; MainSequence's Elaine Stead joins the board.
Also Startup Daily·Startup Daily·Dealroom·This Week in Australian Startups·Dynamic Business
Seven Australian health startups receive equity-free grants totalling $15.6 million in the second CUREator+ round for dementia research, backed by the Medical Research Future Fund, spanning gene editing, medicines and diagnostic tools.
Melbourne dementia drug developer Kinoxis secured $6.75 million equity led by Main Sequence plus a $2.5 million Medical Research Future Fund grant via CUREator+, funding trials of its agitation and pain drug candidates.
UniSuper adds a further $25 million to its backing of Uniseed, reaching $100 million in total support for the university research commercialisation fund; past cheques to quantum and biotech startups are recapped.
Eight Australian health startups received equity-free grants totaling 18.5 million dollars from the CUREator+ program, supported by government funding and delivered with partners Brandon BioCatalyst and ANDHealth.
Weekly roundup detailing five raises across Australian and New Zealand startups — Hapana, Kinoxis Therapeutics, Appetise, Bike Matrix and Aglow — worth a combined $38.5 million, naming lead investors and planned expansion for each.
Australian biotech Kinoxis Therapeutics raised $14.5 million in Series B backing from Uniseed, UniSuper and others to fund Phase 2 trials of KNX100 for dementia-related agitation, including a new Australian study.
Interview with Stoic Venture Capital's Guy Hedley, Craig Swanger and Geoff Waring on backing university science startups, their Uniseed partnership, a planned 2024 All Stars Fund II, and new analyst Safaa Nasrallah.
Uniseed adds Monash and a four-university NSW collaboration, lifting its third fund by $6.75 million to $56.75 million; the article recalls past portfolio sales to Novartis, Shire and Schneider Electric.
University of Sydney spinout Kinoxis Therapeutics signs a licensing and partnership deal with Boehringer Ingelheim to develop psychiatric treatments, with payments and R&D support worth up to $266 million.